Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation

Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation

(2013) D. H. Fowler et al.   BLOOD

Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors

(2013) James N. Kochenderfer et al.   Nature Reviews Clinical Oncology

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

(2013) Stephan A. Grupp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chimeric Antigen Receptor (CAR)-Specific Monoclonal Antibody to Detect CD19-Specific T Cells in Clinical Trials

(2013) Bipulendu Jena et al.   PLoS One

CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia

(2013) R. J. Brentjens et al.   Science Translational Medicine

Dissecting graft-versus-leukemia from graft-versus-host-disease using novel strategies

(2013) E. H. Warren et al.   TISSUE ANTIGENS

Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantation

(2012) N. M. Hardy et al.   BLOOD

Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?

(2012) U. Bacher et al.   BLOOD

Engineered T cells for anti-cancer therapy

(2012) Cameron J Turtle et al.   CURRENT OPINION IN IMMUNOLOGY

T-cell therapy in the treatment of post-transplant lymphoproliferative disease

(2012) Catherine M. Bollard et al.   Nature Reviews Clinical Oncology

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

(2011) J. N. Kochenderfer et al.   BLOOD

Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation

(2011) E. Doubrovina et al.   BLOOD

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

(2011) R. J. Brentjens et al.   BLOOD

Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation

(2011) Claire Roddie et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients

(2011) Barbara Savoldo et al.   JOURNAL OF CLINICAL INVESTIGATION

T cell exhaustion

(2011) E John Wherry   NATURE IMMUNOLOGY

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

(2011) David L. Porter et al.   NEW ENGLAND JOURNAL OF MEDICINE

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

(2011) M. Kalos et al.   Science Translational Medicine

NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation

(2010) David L. Porter et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation

(2010) Steven Z. Pavletic et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Redirected T Cells in Humans

(2010) Michael C. Jensen et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens

(2010) E. H. Warren et al.   BLOOD

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

(2010) J. N. Kochenderfer et al.   BLOOD

Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells

(2010) J. N. Kochenderfer et al.   BLOOD

Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited

(2010) Abhinav Deol et al.   CANCER TREATMENT REVIEWS

Adoptive T cell therapy of cancer

(2010) Malcolm K Brenner et al.   CURRENT OPINION IN IMMUNOLOGY

Natural Expression of the CD19 Antigen Impacts the Long-Term Engraftment but Not Antitumor Activity of CD19-Specific Engineered T Cells

(2010) Eleanor J. Cheadle et al.   JOURNAL OF IMMUNOLOGY

Relapse after Allogeneic Hematopoietic Cell Therapy

(2009) Marcel R.M. van den Brink et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Correlation of pretransplant and early post-transplant response assessment with outcomes after reduced-intensity allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma

(2009) Michael R. Bishop et al.   CANCER

Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation

(2008) M. R. Bishop et al.   ANNALS OF ONCOLOGY

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

(2008) M. Hallek et al.   BLOOD

Donor lymphocyte infusions: the long and winding road: how should it be traveled?

(2008) M Tomblyn et al.   BONE MARROW TRANSPLANTATION